Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 3 - South Korea’s End-of-Life Care Decisions Act: Law for Better End-of-Life Care

  • from Part I - Well-Regulated Jurisdictions
  • Edited by Daisy Cheung, The University of Hong Kong, Michael Dunn, National University of Singapore
  • Book:
    Advance Directives Across Asia
    Published online:
    02 February 2023
    Print publication:
    09 February 2023, pp 57-74
    • Chapter
      • You have access
      • Open access
    • PDF
    • HTML
    • Export citation

  • Summary

    Despite a broad consensus that terminally ill patients should be empowered to choose and deny life-sustaining-treatments (LSTs), South Korea’s path towards the regulation of advance directives was not easy. In this chapter, I sketch the development of social and legal discourse regarding advance directives, from the 1998 Boramae Hospital case to the current Act on Hospice and Palliative Care and Decisions on Life-Sustaining Treatment for Patients at the End of Life (ELDA). I show how ELDA has recognised the patient’s right to decide, and establishes procedures, safeguards and a governance framework for advance directives. Legislation of ELDA occurred in a manner similar to translational research in biomedical science, as new ethical norms gained practical power after being translated, diffused and accepted among practitioners and patients and their families. I also consider how this law connects to practice in different kinds of ways. The necessity of continuing conversation among ethical, legal, medical and governmental actors is emphasised.